Diffuse gliomas are the most common primary malignant brain tumors in adults. Advancements in the molecular profiling of diffuse gliomas in recent years have led to a far better understanding of their biology and clinical outcomes. The fifth edition of the World Health Organization Classification of Central Nervous System Tumors, published in 2021, incorporates this genomic information to a much greater degree than prior editions. It is important for radiologists to understand the new glioma classification system and the characteristic neuroimaging features associated with each entity. This review aims to provide an overview of the diffuse gliomas that can present in adults, with an emphasis on their molecular features and associated imaging findings.
OstromQTPriceMNeffC, et al.CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol2022; 24(Suppl 5): v1–v95.
2.
LouisDNOhgakiHWiestlerOD, et al.The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol2007; 114(2): 97–109.
3.
van den BentMJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol2010; 120(3): 297–304.
4.
LouisDNPerryABurgerP, et al.International society of neuropathology--haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol2014; 24(5): 429–435.
5.
LouisDNPerryAReifenbergerG, et al.The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol2016; 131(6): 803–820.
6.
LouisDNEllisonDWBratDJ, et al.cIMPACT-NOW: a practical summary of diagnostic points from round 1 updates. Brain Pathol2019; 29(4): 469–472.
7.
LouisDNPerryAWesselingP, et al.The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol2021; 23(8): 1231–1251.
8.
MolinaroAMTaylorJWWienckeJK, et al.Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol2019; 15(7): 405–417.
9.
BratDJAldapeKColmanH, et al.cIMPACT-NOW update 3: recommended diagnostic criteria for diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV. Acta Neuropathol2018; 136(5): 805–810.
10.
HartmannCHentschelBWickW, et al.Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol2010; 120(6): 707–718.
11.
TesileanuCMSDirvenLWijnengaMMJ, et al.Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol2020; 22(4): 515–523.
12.
Villanueva-MeyerJEWoodMDChoiBS, et al.MRI features and IDH mutational status of grade II diffuse gliomas: impact on diagnosis and prognosis. AJR Am J Roentgenol2018; 210(3): 621–628.
13.
ChangKBaiHXZhouH, et al.Residual convolutional neural network for the determination of IDH status in low- and high-grade gliomas from MR imaging. Clin Cancer Res2018; 24(5): 1073–1081.
14.
XingZYangXSheD, et al.Noninvasive assessment of IDH mutational status in world health organization grade II and III astrocytomas using DWI and DSC-PWI combined with conventional MR imaging. AJNR Am J Neuroradiol2017; 38(6): 1138–1144.
15.
SuhCHKimHSJungSC, et al.Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis. Eur Radiol2019; 29(2): 745–758.
16.
PatelSHBatchalaPPMuttikkalTJE, et al.Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI marker for isocitrate dehydrogenase (IDH) mutation in glioblastoma. J Neurooncol2021; 152(3): 523–531.
17.
WuCCJainRRadmaneshA, et al.Predicting genotype and survival in glioma using standard clinical MR imaging apparent diffusion coefficient images: a pilot study from the cancer genome atlas. AJNR Am J Neuroradiol2018; 39(10): 1814–1820.
18.
Alvarez-TorresMDMFuster-GarciaEJuan-AlbarracinJ, et al.Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification. BMC Cancer2022; 22(1): 40.
19.
HegiMEDiserensACGorliaT, et al.MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med2005; 352(10): 997–1003.
20.
SuhCHKimHSJungSC, et al.Clinically relevant imaging features for MGMT promoter methylation in multiple glioblastoma studies: a systematic review and meta-analysis. AJNR Am J Neuroradiol2018; 39(8): 1439–1445.
21.
RomanoACalabriaLFTavantiF, et al.Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status. Eur Radiol2013; 23(2): 513–520.
22.
HerrlingerUJonesDTWGlasM, et al.Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathol2016; 131(2): 309–319.
23.
ChenSTanakaSGianniniC, et al.Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol2013; 112(2): 267–275.
24.
KwonMJKangSYChoH, et al.Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases. Brain Pathol2020; 30(2): 235–245.
25.
KozakKRMahadevanAMoodyJS. Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro Oncol2009; 11(2): 183–191.
26.
YiXCaoHTangH, et al.Gliosarcoma: a clinical and radiological analysis of 48 cases. Eur Radiol2019; 29(1): 429–438.
27.
OhJEOhtaTNonoguchiN, et al.Genetic alterations in gliosarcoma and giant cell glioblastoma. Brain Pathol2016; 26(4): 517–522.
28.
KozakKRMoodyJS. Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis. Neuro Oncol2009; 11(6): 833–841.
29.
Meyer-PuttlitzBHayashiYWahaA, et al.Molecular genetic analysis of giant cell glioblastomas. Am J Pathol1997; 151(3): 853–857.
30.
ParsonsDWJonesSZhangX, et al.An integrated genomic analysis of human glioblastoma multiforme. Science2008; 321(5897): 1807–1812.
31.
YanHParsonsDWJinG, et al.IDH1 and IDH2 mutations in gliomas. N Engl J Med2009; 360(8): 765–773.
32.
TesileanuCMSVallentgoedWRSansonM, et al.Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathol2021; 141(6): 945–957.
33.
PoetschLBronnimannCLoiseauH, et al.Characteristics of IDH-mutant gliomas with non-canonical IDH mutation. J Neurooncol2021; 151(2): 279–286.
34.
BananRStichelDBleckA, et al.Infratentorial IDH-mutant astrocytoma is a distinct subtype. Acta Neuropathol2020; 140(4): 569–581.
35.
Cancer Genome Atlas Research NetworkBratDJVerhaakRGAldapeKD, et al.Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med2015; 372(26): 2481–2498.
36.
KannanKInagakiASilberJ, et al.Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget2012; 3(10): 1194–1203.
37.
LouisDNGianniniCCapperD, et al.cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol2018; 135(4): 639–642.
38.
AppayRDehaisCMaurageCA, et al.CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol2019; 21(12): 1519–1528.
39.
ShirahataMOnoTStichelD, et al.Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol2018; 136(1): 153–166.
40.
ReussDEMamatjanYSchrimpfD, et al.IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol2015; 129(6): 867–873.
41.
PatelSHPoissonLMBratDJ, et al.T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res2017; 23(20): 6078–6085.
42.
BatchalaPPMuttikkalTJEDonahueJH, et al.Neuroimaging-based classification algorithm for predicting 1p/19q-codeletion status in IDH-mutant lower grade gliomas. AJNR Am J Neuroradiol2019; 40(3): 426–432.
43.
JohnsonDRKaufmannTJPatelSH, et al.There is an exception to every rule-T2-FLAIR mismatch sign in gliomas. Neuroradiology2019; 61(2): 225–227.
44.
JainRJohnsonDRPatelSH, et al.Real world use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas. Neuro Oncol2020; 22(7): 936–943.
45.
LasockiAAnjariMÖrs KokurcanS, et al.Conventional MRI features of adult diffuse glioma molecular subtypes: a systematic review. Neuroradiology2021; 63(3): 353–362.
46.
AliottaENourzadehHBatchalaPP, et al.Molecular subtype classification in lower-grade glioma with accelerated DTI. AJNR Am J Neuroradiol2019; 40(9): 1458–1463.
47.
DarvishiPBatchalaPPPatrieJT, et al.Prognostic value of preoperative MRI metrics for diffuse lower-grade glioma molecular subtypes. AJNR Am J Neuroradiol2020; 41(5): 815–821.
48.
JoynerDAGarrettJBatchalaPP, et al.MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma. Neuroradiology2023; 65(1): 121–129.
49.
ParkYWParkKSParkJE, et al.Qualitative and quantitative magnetic resonance imaging phenotypes may predict CDKN2A/B homozygous deletion status in isocitrate dehydrogenase-mutant astrocytomas: a multicenter study. Korean J Radiol2023; 24(2): 133–144.
50.
SahmFReussDKoelscheC, et al.Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol2014; 128(4): 551–559.
51.
BallMKKollmeyerTMPraskaCE, et al.Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas. Neurooncol Adv2020; 2(1): vdaa109.
52.
PekmezciMRiceTMolinaroAM, et al.Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol2017; 133(6): 1001–1016.
53.
AokiKNakamuraHSuzukiH, et al.Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol2018; 20(1): 66–77.
54.
KomoriT. Grading of adult diffuse gliomas according to the 2021 WHO classification of tumors of the central nervous system. Lab Invest2022; 102(2): 126–133.
55.
JohnsonDRDiehnFEGianniniC, et al.Genetically defined oligodendroglioma is characterized by indistinct tumor borders at MRI. AJNR Am J Neuroradiol2017; 38(4): 678–684.
56.
YamauchiTOhnoMMatsushitaY, et al.Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas. Brain Tumor Pathol2018; 35(3): 148–158.
57.
van LentDIvan BaarsenKMSnijdersTJ, et al.Radiological differences between subtypes of WHO 2016 grade II-III gliomas: a systematic review and meta-analysis. Neurooncol Adv2020; 2(1): vdaa044.
58.
LasockiAGaillardFGorelikA, et al.MRI features can predict 1p/19q status in intracranial gliomas. AJNR Am J Neuroradiol2018; 39(4): 687–692.
59.
ZhaoKSunGWangQ, et al.The diagnostic value of conventional MRI and CT features in the identification of the IDH1-mutant and 1p/19q co-deletion in WHO grade II gliomas. Acad Radiol2021; 28(7): e189–e198.
60.
SaitoTMuragakiYMaruyamaT, et al.Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas. Brain Tumor Pathol2016; 33(3): 175–182.
61.
PatelSHBatchalaPPMrachekEKS, et al.MRI and CT identify isocitrate dehydrogenase (IDH)-mutant lower-grade gliomas misclassified to 1p/19q codeletion status with fluorescence in situ hybridization. Radiology2020; 294(1): 160–167.
62.
ZhengLGongJYuT, et al.Diffuse midline gliomas with histone H3 K27M mutation in adults and children: a retrospective series of 164 cases. Am J Surg Pathol2022; 46(6): 863–871.
63.
LasockiAAbdallaGChowG, et al.Imaging features associated with H3 K27-altered and H3 G34-mutant gliomas: a narrative systematic review. Cancer Imaging2022; 22(1): 63.
64.
CrowellCMata-MbembaDBennettJ, et al.Systematic review of diffuse hemispheric glioma, H3 G34-mutant: outcomes and associated clinical factors. Neurooncol Adv2022; 4(1): vdac133.
65.
PicartTBarritaultMPoncetD, et al.Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults. Neurooncol Adv2021; 3(1): vdab061.
66.
KaleliogluTEmersonDLukA, et al.Imaging features of diffuse hemispheric glioma, H3 G34-mutant: report of 4 cases. J Neuroradiol2022; S0150-9861.
67.
Tauziede-EspariatADebilyMACastelD, et al.An integrative radiological, histopathological and molecular analysis of pediatric pontine histone-wildtype glioma with MYCN amplification (HGG-MYCN). Acta Neuropathol Commun2019; 7(1): 87.
68.
Guerreiro StucklinASRyallSFukuokaK, et al.Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun2019; 10(1): 4343.
69.
GiannoFGiovannoniICafferataB, et al.Paediatric-type diffuse high-grade gliomas in the 5th CNS WHO classification. Pathologica2022; 114(6): 422–435.
70.
EllisonDWHawkinsCJonesDTW, et al.cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation. Acta Neuropathol2019; 137(4): 683–687.
71.
AlRayahiJZapotockyMRamaswamyV, et al.Pediatric brain tumor genetics: what radiologists need to know. Radiographics2018; 38(7): 2102–2122.
72.
KurokawaRBabaAEmileP, et al.Neuroimaging features of angiocentric glioma: a case series and systematic review. J Neuroimaging2022; 32(3): 389–399.
73.
KaleliogluTRamaBChoBB, et al.Pediatric-type diffuse low-grade glioma with MYB/MYBL1 alteration: report of 2 cases. Neuroradiol J2022; 36: 232–235.
74.
ChiangJHarreldJHTinkleCL, et al.A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration. Acta Neuropathol2019; 138(6): 1091–1092.
75.
HuseJTSnuderlMJonesDT, et al.Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathol2017; 133(3): 417–429.
76.
KurokawaMKurokawaRCapizzanoAA, et al.Neuroradiological features of the polymorphous low-grade neuroepithelial tumor of the young: five new cases with a systematic review of the literature. Neuroradiology2022; 64(6): 1255–1264.
77.
FabbriVPCaporaliniCAsioliS, et al.Paediatric-type diffuse low-grade gliomas: a clinically and biologically distinct group of tumours with a favourable outcome. Pathologica2022; 114(6): 410–421.
